Therapeutic vaccination against HIV

References

• Shearer GM, Clerici M. Early T-helper cell defects in HIV infection. AIDS5, 245–253 (1991).
   PubMed Web of Science ®Google Scholar
• Wahren B, Morfeldt-Mansson L, Biberfeld G et al Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection. N Engl. Med 315,393–394 (1986).
   PubMedGoogle Scholar
• Andersson J, Behbahani H, Lieberman Jet al Perform n is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. AIDS 13(11), 1295–1303 (1999).
   Google Scholar
• Champagne P, Ogg GS, King AS et al Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410, 106–111 (2001).
   PubMed Web of Science ®Google Scholar
• Appay V, Dunbar PR, Callan M et al Memory CD8 + T cells vary in differentiation phenotype in different persistent virus infections. Nature Med. 8, 379–385 (2002).
   PubMed Web of Science ®Google Scholar
• Peters B. HIV immunotherapeutic vaccines. Antivir. Chem. Chemother11, 311–320 (2001).
   Google Scholar
• Nabel G. Challenges and opportunities for development of an AIDS vaccine. Nature410,1002–1007 (2001).
   PubMed Web of Science ®Google Scholar
• Imami N, Gotch E Prospects for immune reconstitution in HIV-1 infection. Gun. Immunol 127,402–411 (2002).
   Google Scholar
• McMichael AJ, Hanke T HIV vaccines 1983-2003. Nature Med 9, 874–880 (2003).
   PubMed Web of Science ®Google Scholar
• Wahren B, Ljungberg K, Kjerrström Zuber A, Zuber B. In: !!!!!!Genetic Immunization Against HIVErt1 H (Ed.), Plenum Publishers, NY, USA (2003).
   Google Scholar
• Gupta M, Mahanty S, Greer P et al Persistent infection with ebola virus under conditions of partial immunity. J. Vim/. 78, 958–967 (2004).
   Google Scholar
• Liu MA. DNA vaccines: a review. j Int.Merl 253,402–410 (2003).
   Google Scholar
• Robinson HL, Hunt LA, Webster RG. Protection against a lethal influenza virus challenge by immunization with a hemagglutinin-expressing plasmid DNA. Vaccine11,957–960 (1993).
   Google Scholar
• •An early observation of protection against infection by DNA-based immunization. The inoculation of an influenza H7 hemagglutinin-expressing DNA protected chickens against lethal challenge with an H7N7 influenza virus.
   Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE et al Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259,1745–1749 (1993).
   PubMed Web of Science ®Google Scholar
• •First example of cell-mediated immunity after immunization with plasmid DNA encoding influenza A nucleoprotein. This resulted in the generation of antigen-specific cytotoxic T-lymphocytes (CTLs) and protection from a subsequent challenge with a heterologous strain of influenza A virus.
   Google Scholar
• Wang B, Ugen KE, Srikantan V et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl Acad. Sri. USA 90(9), 4156–4160 (1993).
   Google Scholar
• Liu M, Fu TM, Donnelly JJ, Caulfield MJ, Ulmer JB. DNA vaccines: mechanisms for generation of immune responses. Adv. Exp. Merl Biol. 452, 187–191 (1998).
   Google Scholar
• Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270, 299–302 (1995).
   Google Scholar
• Berglund P Smerdou C, Fleeton FleetonM, Tubulelcas I, Liljeström P Enhancing immune responses using suicidal DNA vaccines. Nature Biotechnol 16, 562–565 (1998).
   Google Scholar
• Tartaglia J, Excler JL, El Habib R et al. Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV AIDS Res. Hum. Retrovir 14\(Suppl. 3), S291—S298 (1998).
   Google Scholar
• •Discusses the value of priming and boosting with different types of vaccines for HIV.
   Google Scholar
• Sutter G, Haas J. Novel vaccine delivery systems: solutions to HIV vaccine dilemmas? AIDS15, S139—S145 (2001).
   Google Scholar
• Ferrari G, Humphrey W McElrath MJ et al Clade-B-based HIV-1 vaccines elicit cross-clade cytotoxic lymphocyte reactivities in uninfected volunteers. Proc. Natl Acad. Li. USA 94, 1396–1401 (1997).
   Google Scholar
• Seder RA, Hill AV. Vaccines against intracellular infections requiring cellular immunity. Nature 406, 793–798 (2000).
   PubMed Web of Science ®Google Scholar
• Shiver JW, Fu TM, Chen L et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331–335 (2002).
   PubMed Web of Science ®Google Scholar
• •Plasmid DNA vector, the modified vaccinia Ankara (1\4VA) virus, and a replication-incompetent adenovirus type 5 vector, all expressing the SW gag protein were compared for their ability to elicit immune responses. Macaques immunized with Ad5 vector and challenged with a pathogenic SHIV exhibited the most pronounced attenuation of the virus challenge.
   Google Scholar
• Klinger JM, Himathongkham S, Legg H, Luciw PA, Barnett SW Infection of baboons with a simian immunodeficiency virus/HIV-1 chimeric virus constructed with an HIV-1 Thai subtype E envelope. AIDS12, 849–857 (1998).
   Google Scholar
• Gilljam G, Svensson A, Ekstrom A, Wahren B. Immunological responses to envelope glycoprotein 120 from subtypes of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 15, 899–907 (1999).
   Google Scholar
• Redfield R, Birx D, Ketter N et al A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. New Engl. I Med. 324, 1677–1684 (1991).
   Google Scholar
• •HIV-specific immune response could be generated by postinfection vaccination with an HIV envelope antigen, gp160. Both humoral and cellular immunity to HIV increased in response to vaccination. Seroconversion to selected sites and T-cell proliferative responses to gp160 were observed. Responses were associated with the CD4 cell count and with the number of injections administered.
   Google Scholar
• Sandstrom E, Wahren B. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet 353(9166), 1735–1742 (1999).
   Google Scholar
• •835 HIV-seropositive patients with CD4 cell counts above 200/pl were randomly assigned to receive 160 pg of rgp160 or placebo every 3 months for 3 years. A higher proportion of the vaccine group had CD4 cell counts higher than baseline at 6 months. There were significantly fewer deaths among the vaccine recipients than among the placebo-group patients at 2 years, but not at the end of the study.
   Google Scholar
• Leandersson L. The Central Role of the CD4Thelper Cell in HIV Infection. Karolinska Institute, Stockholm, Sweden (2001).
   Google Scholar
• Kong W-P, Huang Y, Yang Z-Y et al Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNAvaccine.j Viral 77, 12764–12772 (2003).
   PubMedGoogle Scholar
• Ljungberg K, Rollman E, Eriksson L, Hinkula J, Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 302, 44–57 (2002).
   Google Scholar
• Rollman E, Hinkula J, Arteaga J et al. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Therapy (2004). Epub ahead of print.
   Google Scholar
• Hioe CE, Jones GJ, Rees AD et al Anti- CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120. AIDS Res. Hum. Retroviruses 16, 893–905 (2000).
   Google Scholar
• Takahashi M, Osono E, Nakagawa Y et al Rapid induction of apoptosis in CD8+ HIV-1 envelope-specific murine CTLs by short exposure to antigenic peptide. Immunol 169, 6588–6593 (2002).
   Google Scholar
• Purtscher M, Trkola A, Grassauer PM et al Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS 10, 587–593 (1996).
   PubMed Web of Science ®Google Scholar
• Schwartz S, Campbell M, Nasioulas G et al. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. Vim!. 66, 7176–7182 (1992).
   Google Scholar
• Phillips RE, Rowland-Jones S, Nixon D et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354, 453–459 (1991).
   PubMed Web of Science ®Google Scholar
• Iroegbu J, Birk M, Lazdina U, Sönnerborg A, Sallberg M. Variability and immunogenicity of human immunodeficiency virus type 1 p24 gene quasispecies. Clin. Diagn. Lab. Imm. 7, 377–383 (2000).
   Google Scholar
• Wahren B, Hinkula J, Stahle EL, Borrebaeck CA, Schwartz S, Wigzell H. Nucleic acid vaccination with HIV regulatory genes. Ann. NY Acad. Li. 772, 278–281 (1995).
   PubMedGoogle Scholar
• Cafaro A, Caputo A, Fracasso C et al Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nature Merl 5, 643–650 (1999).
   Google Scholar
• Kjerrström A, Wahren B. Expression of HIV regulatory DNA vaccine constructs.Biogenic Arnines15(1), 93–112 (1999).
   Google Scholar
• Osterhaus AD, Van Baalen CA, Gruters RA et al Vaccination with Rev and Tat against AIDS. Vaccine 17, 2713–2714 (1999).
   PubMed Web of Science ®Google Scholar
• Tahtinen M, Ranki A, Valle SL, Ovod V, Krohn K. B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains. Domed. Pharmacother. 51(10), 480–487 (1997).
   Google Scholar
• Brander C, Walker BD. T lymphocyte responses in HIV-1 infection: implications for vaccine development. CUI7: Opin. Immunol 11(4), 451–459 (1999).
   Google Scholar
• Leandersson A-C, Gilljam G, Fredriksson M et al Cross-reactive T-helper responses in patients infected with different subtypes of human immunodeficiency virus type 1.Vim!. 74, 4888–4890 (2000).
   Google Scholar
• Calarota SA, Wahren B. Cellular HIV-1 immune responses in natural infection and after genetic immunization. Scam! J. Infect. Dis. 33(2), 83–96 (2001).
   Google Scholar
• Brander C, Rivière Y. Early and late cytotoxic T lymphocyte responses in HIV infection. AIDS16, 597—S103 (2003).
   Google Scholar
• •Summarizes differences of early broad but weak cytotoxicity in HIV infection compared to late epitope reactivity which is directed to fewer epitopes.
   Google Scholar
• Ameisen JC, Guy B, Chamaret S et al Persistent antibody response to the HIV-1-negative regulatory factor in HIV-1-infected seronegative persons. N Engl. Merl 320(4), 251–252 (1989).
   Google Scholar
• Koenig S, Fuerst TR, Wood LV et al Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein. Immund 145(1), 127–135 (1990).
   Google Scholar
• Rowland-Jones S, Sutton J, Ariyoshi K et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Merl 1(1), 59–64 (1995).
   Google Scholar
• •Women with frequent exposure to a range of African HIV-1 variants but who do not become infected have CTLs directed towards HIV epitopes suggesting that they were originally primed by exposure to these virus strains.
   Google Scholar
• Rowland-Jones SL, Dong T, Fowke KR et al. Cytotoxic T-cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. j an. Invest. 102, 1758–1765 (1998).
   PubMed Web of Science ®Google Scholar
• Altfeld M, Addo MM, Eldridge RL et al. Vpr is preferentially targeted by CTL during HIV-1 infection. j Immunol167(5), 2743–2752 (2001).
   Google Scholar
• Haas G, Samri A, Gomard E et al Cytotoxic T-cell responses to HIV-1 reverse transcriptase, integrase and protease. AIDS12(12), 1427–1436 (1998).
   Google Scholar
• Albert J, Abrahamsson B, Nagy K et al Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4,107–112 (1990).
   PubMed Web of Science ®Google Scholar
• Moore JP, Parren PW, Burton DR. Genetic subtypes, humoral immunity and human immunodeficiency virus type 1 vaccine development. Viral. 75 (13), 5721–5729 (2001).
   Google Scholar
• Schmitz JE, Kuroda MJ, Santra S et al. Control of viremia in simian immunodeficiency virus infection by CD8 + lymphocytes. Science 283,857 (1999).
   PubMed Web of Science ®Google Scholar
• Jin X, Bauer DE, Tuttleton SE et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. I Exp. Merl 189,991–998 (1999).
   Google Scholar
• Goulder P, Altfeld M, Rosenberg E et al Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. I Exp. Merl 193, 181–193 (2001).
   PubMed Web of Science ®Google Scholar
• Kaul R, Dong T, Plummer F et al CD8* lymphocytes respond to different HIV epitopes in seronegative and infected subjects. I Clin. Invest. 107,1303-1310 (2001).
   Google Scholar
• Betts MR, Ambrozak DR, Douek DC et al. Analysis of total human immunodeficiency (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. I Virol. 75, 11983–11991 (2001).
   PubMed Web of Science ®Google Scholar
• Draenert R, Altfeld M, Brander C et al. Comparison of overlaping peptide sets for detection of antiviral CD8 and CD4 T cell responses. I Immunol. Meth. 275,19-29 (2003).
   Google Scholar
• Sandberg JK, Leandersson AC, Devito C et al. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization. Vimlogy 273 (1), 112–119 (2000).
   Google Scholar
• Hanke T, McMichael A. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. 'minim& Lett 66(1-3), 177–181 (1999).
   Google Scholar
• •HIV vaccine candidates were constructed as a string of partially overlapping CTL epitopes. These vaccines were shown to induce virus-specific cytolytic CD8+ cells after a single intramuscular needle injection.
   Google Scholar
• Allen TM, O'Connor DH, Jing P et al. Tat- specific cytotoxic T lymphocytes select for SW escape variants during resolution of primary viraemia. Nature 407(6802), 386–390 (2000).
   PubMed Web of Science ®Google Scholar
• Barouch DH, Kunstman J, Kuroda MJ et al Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415,335–339 (2002).
   PubMed Web of Science ®Google Scholar
• Kaech SM, Tan JT, Wherry EJ et al Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nature Immunol. 4,1191–1198 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenwirth B, Bogers WM, Nieuwenhuis IG et al An anti-HIV strategy combining chemotherapy and therapeutic vaccination. Merl Primatol 28,195–205 (1999).
   PubMedGoogle Scholar
• Hel Z, Venzon D, Poudyal M et al Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Natum Merl 6,1140–1146 (2000).
   PubMed Web of Science ®Google Scholar
• Franchini G, Nacsa J, Hel Z, Tryniszewska E. Immune intervention strategies for HIV-1 infection of humans in the SW macaque model. Vaccine 20,52–60 (2002).
   Google Scholar
• Tryniszewska E, Nasca J, Lewis M et al Vaccination of macaques with long-standing SIVmac 251 infection lowers the viral setpoint after cessation of antiretroviral therapy. I Immunology169,5347–5357 (2002).
   Google Scholar
• •Rhesus macaques with long-standing SIVmac251 infection were treated with antiretrovirals and vaccinated with or without IL-2 with a poxvirus vector expressing the SIVmac structural and regulatory genes. Following antiretroviral treatment interruption, the viral set point was significantly lower in vaccinated than in control macaques.
   Google Scholar
• Lori F, Kelly LM, Lisziewicz J. Immunological approaches for HIV therapy. Gun: Drug- Targets Infect. Dirac-U. 3, 171–178 (2003).
   Google Scholar
• Birx DL, Loomis-Price LD, Aronson N et al Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early stage HIV-1-infected volunteers. I Infect. Dis. 181,881-889 (2000).
   Google Scholar
• Goebel FD, Mannhalter JW, Belshe RB et al Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European multinational IMMUNO AIDS vaccine study. AIDS13,1461–1468 (1999).
   Google Scholar
• MacGregor RR, Boyer JD, Ugen KE et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. Infect Dis. 178,92–100 (1998).
   Google Scholar
• •A DNA-based vaccine containing HIV-1 env and rev genes induced antibody and Cu, activity against gp160-bearing targets.
   Google Scholar
• Boyer JD, Chattergoon MA, Ugen KE et al Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial. Gun. Immunol. 90,100-107 (1999).
   Google Scholar
• Jin X, Ramanathan JM, Barsoum S et al Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. I Viral. 76,2206–2216 (2002).
   PubMedGoogle Scholar
• Calarota S, Bratt G, Nordlund S et al Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet351(9112), 1320–1325 (1998).
   Google Scholar
• Calarota SA, Leandersson AC, Bratt G et al Immune responses in asymptomatic HIV-1-infected patients after HIV—DNA immunization followed by highly active antiretroviral treatment. I immund 163(4), 2330–2338 (1999).
   Google Scholar
• Calarota SA, Kjerrstrom A, Islam KB, Wahren B. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. Hum. Gene Ther. 12(13), 1623–1637 (2001).
   Google Scholar
• Lundholm P, Leandersson A-C, Christensson B et al DNA mucosal HIV vaccine in humans. Virus Res. 82(1-2), 141–145 (2002).
   Google Scholar
• Rosenberg ES, Altfeld M, Poon SH et al Immune control of HIV-1 after early treatment of acute infection. Nature 407, 523–526 (2000).
   PubMed Web of Science ®Google Scholar
• Autran B, Carcelain G, Li TS et al. Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease. Science 277, 112–116 (1997).
   PubMed Web of Science ®Google Scholar
• Leandersson A-C, Bratt G, Hinkula J et al Induction of specific T-cell responses in HIV infection. AIDS12,157–166 (1998).
   PubMedGoogle Scholar
• Pitcher CJ, Quittner C, Peterson DM et al HIV-1-specific CD4 + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Med. 5,518–525 (1999).
   PubMed Web of Science ®Google Scholar
• Hejdeman B, Leandersson A-C, Fredriksson E-L et al Better preserved immune responses after immunization with rgpl 60 in HIV-1 infected patients treated with highly active antireroviral therapy than in untreated patients with similar CD4 levels during at 2 years-follow-up. HIV Medicine 4,101–110 (2003).
   Google Scholar
• •Immune responses after rgp160 vaccination were better preserved in HAART-treated patients with low viral loads than in individuals with high viral load and no antiviral treatment, despite comparable CD4 levels.
   Google Scholar
• Maino VC, Suni MA, Wormsley SB et al. Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen. AIDS Res. Hum. Retroviruses 16, 2065-2066 (2000).
   Google Scholar
• MOSS RB, Giermakowska Wallace, W. MR et al. T-helper cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected sujects vaccinated with HIV-1 immunogen (Remune). Gun. Diagn. Lab. Immunol 7, 724–727 (2000).
   Google Scholar
• Robbins GK, Addo MM, Troung H et al Augmentation of HIV-1-specific T Helper cell responses in chronic HIV-infection by therapeutic immunization. A/DS17, 1121–1126 (2003).
   Google Scholar
• Fernandez-Cruz E, Navarro J, Rodriguez- Sainz C et al The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in treatment of HIV infection. Expert Rev Vacci7es2, 739–752 (2003).
   Google Scholar
• •An unblinded study conducted in Europe documented a significant effect on HIV viral load by vaccination with Remune®.
   Google Scholar
• Hejdeman B, Boström A-C, Matsuda R et al DNA immunization with HIV early genes in HIV-1 infected patients on highly active antiretroviral treatment. AIDS Res. Hum. Retroviruses (In Press) (2004).
   Google Scholar
• Cosma A, Nagaraj R, Buhler S et al Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22,21–29 (2003).
   PubMed Web of Science ®Google Scholar
• Schmitt M, Harrer E, Goldwich A et al Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS14(6), 653–658 (2000).
   Google Scholar
• Samri A, Haas G, Duntze J et al Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J: Viral. 74(19), 9306–9312 (2000).
   Google Scholar
• Wahren B, Ljungberg K, Rollman E et al HIV subtypes and recombination strains — strategies for induction of immune responses in man. Vaccine 20,1988–1993 (2002).
   Google Scholar
• Draenert R, Verrill CL, Tang Y et al Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. Viral. 78,630–641 (2004).
   Google Scholar
• Kim JJ, Yang JS, Dentchev T, Dang K, Weiner DB. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J: Interferon Cytokine Res. 20,487–498 (2000).
   PubMed Web of Science ®Google Scholar
• Zuber B, Hinkula J, Levi M et al Induction of immune responses and break of tolerance by DNA against the HIV-1 co-receptor CCR5 but no protections from SW SM challenge. Virology633,1–10 (2000).
   Google Scholar
• Lehner T, Wang Y, Doyle C et al Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SW infection in macaques. Eur. j Immunol 29, 2427–2435 (1999).
   Google Scholar
• Lehner T, Doyle C, Wang Y et al. Immunogenicity of the extracellular domains of C—C chemokine receptor 5 and the in vitro effects on Simian Immunodeficiency Virus or HIV infectivity. J: Immunol 166,7446–7455 (2001).
   Google Scholar
• Markowitz M, Jin X, Hurley A et al Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J: Infect. Dis. 186,634-643 (2002).
   Google Scholar
• •Despite evidence of induction of HIV-1-specific cell-mediated immune responses, plasma viremia was not persistently suppressed in subjects receiving antiretroviral therapy and adjunctive HIV vaccination. Nevertheless, given the transient suppression of viremia observed in nearly all subjects after antiretroviral treatment had been discontinued, further investigations of therapeutic vaccination were considered desirable.
   Google Scholar
• Bratt G, Eriksson LE, Sandstrom E et al Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment. Int. J: STD AIDS 10,514–521 (1999).
   Google Scholar
• Eriksson LE. HIV Therapies. Karolinska Institute, Stockholm, Sweden, 1–37 (2003).
   Google Scholar
• Moss RB, Brandt C, Giermakowska W et al HIV-specific immunity during structured antiviral drug treatment interruption. Vaccine 21,1066–1071 (2003).
   PubMed Web of Science ®Google Scholar